We report the first case of cutaneous leishmaniasis in a patient treated with infliximab. The species was Leishmania infantum, agent of both cutaneous leishmaniasis and visceral leishmaniasis. Cutaneous leishmaniasis occurred after the 9th infusion of infliximab in a patient who was suffering from ankylosing spondylitis.

Keywords:
Leishmaniasis, Leishmania infantum, Cutaneous leishmaniasis, infliximab, Tumor necrosis factor a antagonists
1.
Del Giudice P, Marty P, Lacour JP: Leishmaniose cutanée autochtone en France métropolitaine. Ann Dermatol Venereol 2001;128:1057–1062.
2.
Del Giudice P, Marty P, Lacour JP, Perrin C, Pratlong F, Haas H, Dellamonica P, Le Fichoux Y: Cutaneous leishmaniasis due to Leishmania infantum. Arch Dermatol 1998;134:193–198.
3.
Marty P, Izri A, Ozon C, Haas P, Rosenthal E, Del Giudice P, Godenir J, Coulibaly E, Gari-Toussaint M, Delaunay P, Ferrua B, Haas H, Pratlong F, Le Fichoux Y: A century of leishmaniasis in Alpes-Maritimes, France. Ann Trop Med Parasitol 2007;101:1–12.
4.
Pratlong F, Rioux JA, Marty P, Faraut F, Dereure J, Lamotte G, Dedet JP, Gambarelli F: Isoenzymatic analysis of 712 strains of Leishmania infantum in the south of France and relationship of enzymatic polymorphism to clinical and epidemiological features. J Clin Microbiol 2004;42:4077–4082.
5.
Basset D, Faraut F, Marty P, Dereure J, Rosenthal E, Mary C, Pratlong F, Lachaud L, Bastien P, Dedet JP: Visceral leishmaniasis in organ transplant recipients: 11 new cases and review of the literature. Microb Infect 2005;7:1370–1375.
6.
Alvar J, Canavate C, Guttierez-Solar B, et al: Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997;10:298–319.
7.
Del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, Gastaut JA, Costagliola D, Rosenthal E, the Clinical Epidemiologic Group of the French Hospital Database on HIV: Impact of highly active antiretroviral therapy on the Incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus. J Infect Dis 2002;186:1366–1370.
8.
Fernandez-Guerrero ML, Robles P, Rivas P, Mojer F, Muniz G, De Gorgolas M: Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis. Acta Trop 2004;90:11–16.
9.
Castellino G, Govoni M, Lo Monaco A, Montecucco C, Colombo F, Trotta F: Visceral leishmaniasis complicating a connective tissue disease: three case reports from Italy. Lupus 2004;13:201–203.
10.
Hachicha I, Sellani M, Fourati H, Hidji N, Baklouti S: Cutaneous leishmaniasis in rheumatoid arthritis. Rev Med Interne 2009;30:609–612.
11.
Couppié P, Clyti E, Sobesky M, Bissuel F, Del Giudice P, Sainte-Marie D, Dedet JP, Carme B, Pradinaud R: Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana. Br J Dermatol 2004;151:1165–1171.
12.
Tuon FF, Sabbaga Amato V, Floeter-Winter LM, De Andrade Zampieri R, Amato Neto V, Siqueira Franca FO, Shikanai-Yasuda MA: Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids: first report. Int J Dermatol 2007;46:628–630.
13.
Pittalis S, Nicastri E, Spinazzola F, Ghirga P, De Marco M, Paglia MG, Narciso P: Leishmania infantum leishmaniasis in corticosteroid-treated patients. BMC Infect Dis 2006;18:177.
14.
Gontijo CM, Pacheco RS, Orefice F, Lasmar E, Silva ES, Melo MN: Concurrent cutaneous, visceral and ocular leishmaniasis caused by Leishmania (Viannia) braziliensis in a kidney transplant patient. Mem Inst Oswaldo Cruz 2002;97:751–753.
15.
Titus RG, Sherry B, Cerami A: Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 1989;170:2097–2104.
16.
Murray HW, Jungbluth A, Ritter E, Montelibano C, Marino MW: Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect Immun 2000;68:6289–6293.
17.
Beutler B, Grau GE: Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med 1993;21:S423–S435.
18.
Bagalas V, Kioumis I, Argyropoulou P, Patakas D: Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. Clin Rheumatol 2007;26:1344–1345.
19.
Bassetti M, Pizzorni C, Gradoni L, Del Bono V, Cutolo M, Viscoli C: Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with adalimumab. Rheumatology 2006;45:1446–1448.
20.
Teknokidou MG, Skopouli FN: Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? Clin Rheumatol 2008;27:541–542.
21.
Fabre S, Gibert C, Lechiche C, Dereure J, Jorgensen C, Sany J: Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol 2005;23:891–892.
22.
Ludwig C, Guyon G, Jorgensen C, Rodière M: Présentation à la Société Française de Pédiatrie. 2005. http://www.sfpediatrie.com/uploads/media/complications_infectieuses_des_antiTNF-alphaantagonists_C.Ludwig.pdf.
23.
Romani-Costa V, Sanchez C, Moya F, Estany C: Visceral leishmaniasis related to infliximab administration. Enferm Infecc Microbiol Clin 2004;22:310.
24.
Baixoli Rubio A, Rodriguez Gorriz E, Campos Fernandez C, Calvo Catala J, Garcia Vicente S: Rare opportunistic disease in a patient treated with immunosuppressive therapy for rheumatoid arthritis. An Med Interna 2003;20:276–277.
25.
Balato A, Balato N, Patruno C, Gallo L, Ayala F: Visceral leishmaniasis infection in a patient with psoriasis treated with efalizumab. Dermatology 2008;217:360–361.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.